SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy.

Yoon Kyung ParkParamesh JangiliSoyu ZiRae Hyung KangDokyoung Kim Jong Seung Kim

Published in: Chemical communications (Cambridge, England) (2022)

A new conjugate formulation, SIWV-PB-SN, based on glioblastoma (GBM)-homing SIWV tetrapeptide and an ROS-responsive prodrug is reported. SIWV-PB-SN selectively penetrates the GBM cells and releases anti-GBM drug (SN-38) via ROS-induced linker cleavage. This study presents a new insight for a more advanced therapeutic approach to overcoming GBM.

Keyphrases

cancer therapy
drug delivery
cell death
dna damage
reactive oxygen species
heavy metals
cell cycle arrest
induced apoptosis
high glucose
drug release
oxidative stress
aqueous solution
risk assessment
dna binding
endoplasmic reticulum stress
endothelial cells
replacement therapy